EP300 mediates SREBP-1c acetylation. Elevated SREBP-1c acetylation has been associated with increased lipogenic gene expressionEP300 acetylates FXR, resulting in activation of its target genes. FXR acetylation is constitutively elevated in metabolic disease statesEP300 acetylates ChREBP, a transcriptional activator of glycolytic and lipogenic genesEP300 acetylates HNF4, which is involved in lipid homeostasis and glucose metabolism among othersTranscriptional activation of NF-кB, which induces inflammatory responses, requires association with CBP/p300. Here, EP300 is linked to metabolic disease.